High CXCR4 expression impairs rituximab response and the prognosis of R-CHOP-treated diffuse large B-cell lymphoma patients

Survival of diffuse large B-cell lymphoma (DLBCL) patients has improved by inclusion of rituximab. Refractory/recurrent disease caused by treatment resistance is, however, a major problem. Determinants of rituximab sensitivity are not fully understood, but effect of rituximab are enhanced by antagon...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Oncotarget
Asıl Yazarlar: Laursen, Maria Bach, Reinholdt, Linn, Schönherz, Anna Amanda, Due, Hanne, Jespersen, Ditte Starberg, Grubach, Lykke, Ettrup, Marianne Schmidt, Røge, Rasmus, Falgreen, Steffen, Sørensen, Suzette, Bødker, Julie Støve, Schmitz, Alexander, Johnsen, Hans E., Bøgsted, Martin, Dybkær, Karen
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Impact Journals LLC 2019
Konular:
Research Paper
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC6366826/
https://ncbi.nlm.nih.gov/pubmed/30774774
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.26588
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller